Form 4: Bio-Key International Director Acquires Shares in Lieu of Board Fees

Director Emmanuel Alia receives 1,429 shares of Bio-Key International common stock on March 27, 2024, as payment for board meeting attendance fees.

Summary

• On March 27, 2024, Emmanuel Alia, a director of Bio-Key International, Inc., acquired 1,429 shares of common stock.
• The shares were issued under the company's Amended and Restated 2015 Equity Incentive Plan.
• These shares were provided as payment for board meeting attendance fees.
• Following the transaction, Alia directly owns 3,368 shares of Bio-Key International.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine transaction related to director compensation.

Positives

• The acquisition of shares by a director demonstrates their continued involvement and alignment with the company's interests.

Industry Context

This type of equity compensation is common practice for board members, especially in smaller companies, to align their interests with shareholders and conserve cash.

Comparison to Industry Standards

• Equity compensation for board members is a standard practice across various industries, particularly in technology and growth-oriented companies.
• Companies like Okta and CrowdStrike also utilize equity grants as part of their board compensation packages.
• The amount of equity granted typically depends on the company's size, stage, and overall compensation strategy.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it aligns the director's interests with the company's performance.

Key Dates

Keywords

Bio-Key International, Director, Share Acquisition, Equity Incentive Plan, Board Fees, BKYI, Common Stock